Financial Performance - The company's revenue for Q1 2024 was RMB 3,242.81 million, a decrease of 4.99% compared to RMB 3,413.06 million in the same period last year[4] - Net profit attributable to shareholders was RMB 607.82 million, an increase of 4.45% from RMB 581.91 million year-on-year[4] - Basic and diluted earnings per share were both RMB 0.65, reflecting a growth of 4.84% from RMB 0.62 in the same quarter last year[4] - The total comprehensive income for the period was RMB 693,127,170.79, compared to RMB 547,848,808.47 in the previous year, indicating a growth of 26.5%[25] - The investment income decreased by 58.41% to RMB 15.72 million, down from RMB 37.80 million in the previous year, primarily due to last year's dividend income[12] Cash Flow - The net cash flow from operating activities surged by 208.30%, reaching RMB 924.25 million compared to RMB 299.78 million in the previous year[4] - The net cash flow from operating activities increased significantly to ¥924,248,920.31, compared to ¥299,784,593.85 in the previous period, marking a growth of approximately 208%[27] - Cash inflow from operating activities totaled ¥3,508,763,815.99, up from ¥3,446,124,787.42, indicating a slight increase of about 1.8%[27] - Cash outflow from operating activities decreased to ¥2,584,514,895.68 from ¥3,146,340,193.57, representing a reduction of approximately 17.9%[27] - The net cash flow from investing activities was negative at -¥457,336,601.18, worsening from -¥64,826,182.09 in the previous period[27] - The net cash flow from financing activities showed a net outflow of RMB 654.61 million, a decrease of 306.71% compared to a net inflow of RMB 316.69 million in the previous year, due to reduced new borrowings and increased loan repayments[14] Assets and Liabilities - Total assets at the end of the reporting period were RMB 25,189.70 million, a slight increase of 0.58% from RMB 25,044.83 million at the end of the previous year[5] - The total liabilities decreased to RMB 9,750,195,000.46 from RMB 10,278,124,131.71, reflecting a reduction of approximately 5.12%[24] - The total current assets as of March 31, 2024, amounted to RMB 17,178,219,962.61, a slight decrease from RMB 17,266,174,718.28 at the beginning of the year[23] - The total non-current assets increased to RMB 8,011,475,794.50 from RMB 7,778,652,409.47 at the beginning of the year[23] Shareholder Information - Shareholders' equity attributable to the parent company increased by 4.01% to RMB 14,606.16 million from RMB 14,042.50 million[5] - The total number of ordinary shareholders at the end of the reporting period was 43,751, with the top ten shareholders holding 33.41% of the shares[15] - As of March 31, 2024, the company repurchased a total of 2,152,600 A-shares, accounting for 0.23% of the total share capital, with a total expenditure of RMB 73,436,534.00[18] - The company also repurchased 2,476,300 H-shares, representing 0.27% of the total share capital, with a total expenditure of HKD 60,363,260.00[19] Operational Highlights - The company plans to continue expanding its market presence and investing in new product development to drive future growth[3] - The company reported a significant increase in minority shareholders' profit, which rose by 238.80% to RMB 108.26 million from RMB 31.95 million in the previous year[12] - The revenue from gastrointestinal products decreased by 25.68% to RMB 588.96 million, while revenue from hormone products increased by 39.89% to RMB 806.93 million[12] - The company experienced a 60.26% increase in revenue from diagnostic reagents and equipment, reaching RMB 235.58 million compared to the previous year[12] Expenses - Research and development expenses for the quarter were RMB 238,173,559.46, down 23.5% from RMB 311,408,248.52 in the previous year[25] - The company reported a decrease in sales expenses to RMB 876,113,247.33 from RMB 964,906,980.93, a decline of 9.2%[25] - The company reported a 522.72% increase in financial expenses, primarily due to increased interest income from deposits[12] Stock Options - The company has a total of 1,001 incentive participants eligible to exercise 7,045,000 stock options at an exercise price of RMB 31.31 per A-share[20] - As of March 31, 2024, 270.66 thousand stock options have been exercised by the incentive participants[21] Buyback Information - The highest purchase price for A-shares during the buyback was RMB 35.15 per share, while the lowest was RMB 32.95 per share[18] - The highest purchase price for H-shares during the buyback was HKD 25.15 per share, with a lowest price of HKD 23.05 per share[19] Cash and Cash Equivalents - The company's cash and cash equivalents stood at RMB 11,143,148,609.60, a decrease from RMB 11,325,723,855.76 at the beginning of the year[23] - The ending cash and cash equivalents balance was ¥10,787,974,836.57, slightly down from ¥10,600,468,696.85[27] Audit Information - The company did not undergo an audit for the first quarter report[28]

Financial Performance - In 2023, the company achieved operating revenue of RMB 12,430.04 million, a year-on-year decrease of 1.58%[9] - The net profit attributable to shareholders was RMB 1,953.65 million, representing a year-on-year increase of 2.32%[9] - The proposed profit distribution plan for 2023 includes a cash dividend of RMB 13.50 per 10 shares, subject to approval at the annual general meeting[22] - The company reported a significant increase in revenue, achieving a total of RMB 1.5 billion, representing a year-over-year growth of 20%[37] - The net cash flow from operating activities increased by 17.18% to CNY 3,248,934.19 in 2023[38] - The total assets as of December 31, 2023, were CNY 25,044,827.13, representing a 0.71% increase from the beginning of the year[39] - The total liabilities increased by 3.49% to CNY 10,278,124.13 as of December 31, 2023[39] - The return on equity for 2023 was 14.00%, a decrease of 0.31 percentage points from the previous year[39] - Basic earnings per share for 2023 were CNY 2.10, up 2.94% from CNY 2.04 in 2022[38] Research and Development - The company has made significant progress in R&D, with multiple products including injectable Triptorelin microspheres and Voriconazole approved for market[10] - The company is focusing on high-barrier complex formulations and innovative drugs in fields such as oncology and reproductive health[10] - Over 65% of participants have been enrolled in the Phase III clinical trial for recombinant human follicle-stimulating hormone injection[11] - The company aims to enhance its leading advantages in innovative drugs and high-barrier complex formulations, focusing on areas such as digestive, mental health, reproductive assistance, and anti-tumor fields[15] - The company is committed to enhancing its research and development capabilities, with ongoing projects in various therapeutic areas, which will support long-term growth[104] - The company reported a total R&D investment of approximately RMB 1.24 billion in 2023, a decrease of 11.86% compared to RMB 1.40 billion in 2022[107] - The number of R&D personnel decreased by 6.89% to 906 in 2023, down from 973 in 2022[106] Market Expansion and Strategy - The company has initiated international collaborations and licensing agreements to expand its product pipeline and market reach[13] - The company is expanding its market presence in Southeast Asia, targeting a 10% market share within the next two years[37] - The company is actively expanding its international business, with ongoing sales and registration efforts in countries like Pakistan, Indonesia, and the Philippines[60] - The company is focusing on unmet clinical needs and investing in innovative drug development to ensure sustainable growth[195] - The company plans to advance the development of traditional Chinese medicine formulations and enhance the marketing of key products in oncology and antiviral sectors[186] Corporate Social Responsibility and Sustainability - The company’s MSCI ESG rating achieved the highest level of AAA, becoming the first Chinese pharmaceutical company to receive this rating[14] - The company is committed to social responsibility, covering 8 provinces and 4 autonomous regions with its chronic disease prevention project[14] - The company has set a goal to achieve carbon neutrality by 2055, emphasizing its commitment to sustainable development and environmental protection[16] - The company is committed to strict compliance with environmental regulations and aims to achieve carbon neutrality by 2055[198] Marketing and Sales - The company is enhancing its marketing strategies through evidence-based and collaborative marketing approaches[12] - The company has strengthened its marketing management and established key product line divisions to enhance customer market share in three major areas[70] - The marketing strategy includes rapid coverage of core products, particularly in the digestive field, and expanding market presence in assisted reproduction and mental health sectors[182] Investment and Financial Management - The company has implemented new strategies focusing on digital marketing, which is expected to improve customer engagement by 30%[37] - The company plans to invest RMB 200 million in upgrading its manufacturing facilities to meet international quality standards[37] - The company has reported a total investment in securities of approximately RMB 236.5 million, with a loss of RMB 24.38 million during the reporting period[155] - The company has established measures to mitigate market risks associated with foreign exchange operations, ensuring that these contracts are not used for speculative trading[159] Investor Relations - The company engaged in multiple investor communications throughout January to July 2023, primarily through phone calls with institutional investors[199] - The investor relations activities were documented and made available on the company's official website, ensuring accessibility of information to stakeholders[199] - The company has maintained transparency in its communications, responding to inquiries based on actual operational conditions[199]

Financial Performance - For the year 2023, the company achieved a revenue of RMB 12,430.04 million, a year-on-year decrease of 1.58%[16] - The net profit attributable to shareholders for 2023 was RMB 1,953.65 million, representing a year-on-year increase of 2.32%[16] - Excluding non-recurring gains and losses, the net profit from core business for 2023 was RMB 1,881.35 million, a slight increase of 0.05% year-on-year[16] - The company reported total operating revenue of RMB 12,430.04 million, representing a year-on-year increase of 2.94%[28] - The net profit attributable to shareholders was RMB 1,744.89 million, reflecting a growth of 14.04% compared to the previous year[29] - The company reported a net profit of RMB 581,909,331.89 thousand in the first quarter of 2023[65] - The company reported a total operating cost of RMB 4,465,473,361.10, a slight increase of 0.09% from RMB 4,461,283,076.09 in 2022[118] - The income tax expense for the year was RMB 485.07 million, an increase of 29.36% year-on-year, primarily due to the company's operating results[129] - The company has made adjustments to previous years' financial data due to changes in accounting policies[58] Dividend and Shareholder Returns - The board proposed a cash dividend of RMB 13.50 per 10 shares (before tax) for the 2023 fiscal year, pending approval at the annual general meeting[17] - The company plans to distribute a cash dividend of RMB 13.50 per 10 shares to all shareholders, pending approval at the 2023 annual general meeting[37] - The dividend distribution is expected to occur on July 8, 2024, for A-share shareholders and August 5, 2024, for H-share shareholders[37] Research and Development - In 2023, the company focused on R&D innovation, particularly in the fields of digestive, mental health, reproductive assistance, and oncology, enhancing its differentiated product pipeline[18] - The company has established a robust R&D innovation system, optimizing management structures across clinical operations and drug safety, leading to accelerated realization of innovative research outcomes[18] - The company aims to enhance R&D efficiency and strengthen its leading position in innovative drugs and complex formulations, focusing on areas such as digestive, mental health, reproductive assistance, and oncology[24] - The company has initiated multiple clinical trials, including a Phase III trial for recombinant human IL-17A/F monoclonal antibody injection and completed enrollment for semaglutide injection for type 2 diabetes[20] - The company has made significant progress in R&D, with the approval of the injection of Triptorelin Acetate microspheres for prostate cancer and the completion of Phase III clinical trials for endometriosis[78] - The company is advancing several R&D projects, including a long-acting implant for prostate cancer and a micro-injection for endometriosis, all in preclinical research stages[137] Market Expansion and Product Development - The company accelerated the internationalization of its products, contributing to a comprehensive enhancement of its long-term sustainable development capabilities[14] - The company introduced innovative drugs in the gastrointestinal and cardiovascular fields, strengthening its international collaboration and licensing efforts[21] - The company has analyzed potential risk factors and response strategies for future development in the management discussion and analysis section of the report[37] - Livzon plans to expand its market presence in Southeast Asia, targeting a 30% increase in sales from this region by 2025[45] - The company is actively pursuing international collaboration and innovation business models to enhance its global market presence[69] - The company is focusing on high-barrier complex formulations and innovative drugs, strengthening its integrated raw material and formulation capabilities[98] Environmental and Social Responsibility - The company achieved an MSCI ESG rating of AAA, becoming the first Chinese pharmaceutical company to receive this highest rating[23] - The company plans to achieve carbon neutrality by 2055 and is committed to increasing environmental protection investments[26] Financial Position and Assets - The total assets as of December 31, 2023, were RMB 25,044,827.13 thousand, reflecting a 0.71% increase from the previous year[59] - The total liabilities increased by 3.49% to RMB 10,278,124.13 thousand as of December 31, 2023[59] - The return on equity attributable to shareholders was 13.91%, an increase of 0.15 percentage points compared to the previous year[59] - The company's asset-liability ratio increased from 39.94% in 2022 to 41.04% in 2023[157] - The total outstanding debt as of December 31, 2023, is RMB 5,014.84 million, an increase from RMB 4,604.43 million as of December 31, 2022, representing an increase of 8.9%[171] Risk Management and Compliance - The company has implemented long-term equity incentive plans to motivate employees and align their growth with the company's development[23] - The company continues to address corruption issues in the pharmaceutical industry through a comprehensive governance approach initiated by the National Health Commission[3] - Forward-looking statements in the report are subject to risks and uncertainties, and actual results may differ significantly from these statements[37] Investment and Financing Activities - The company has made significant equity investments, including RMB 600 million in Wuhan Kangli Health Investment, acquiring a 60% stake, and RMB 102 million in Guangdong Lijian Animal Health, acquiring a 51% stake[183] - The total investment amount for the year reached RMB 729.64 million, a significant increase of 1,724.08% compared to RMB 40.00 million in the previous year[182] - The company has capital commitments totaling RMB 709.93 million, which includes commitments for long-term asset construction and R&D expenditures[168] Product Pipeline and Approvals - The company has successfully launched several new products, including tocilizumab injection and new indications for injectable esomeprazole sodium, enhancing its product pipeline in various therapeutic areas[131] - The company has received emergency use authorization for the recombinant novel coronavirus fusion protein vaccine, which is expected to enrich its vaccine product pipeline[133] - The injectable progesterone solution for women undergoing assisted reproductive technology has been submitted for approval, aiming to expand the company's offerings in the reproductive health sector[133] - The injectable phosphoric acid tedizolid for acute bacterial skin and skin structure infections has been submitted for market approval, which will enhance the company's infection control product pipeline[133]

证券代码：000513、01513 证券简称：丽珠集团、丽珠医药 公告编号：2023-109 丽珠医药集团股份有限公司 关于为下属附属公司提供担保的月度进展公告 本公司及董事会全体成员保证信息披露内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 重要内容提示： ●2023 年 11 月，丽珠医药集团股份有限公司（以下简称"公司"或"丽珠 集团"）与招商银行股份有限公司珠海分行（以下简称"招商银行"）签署了《最 高额不可撤销担保书》，被担保人为珠海市丽珠单抗生物技术有限公司（以下简 称"丽珠单抗"），担保期限为自单笔授信业务的主合同签订之日起至债务人在该 主合同项下的债务履行期限届满日后三年止，担保金额为人民币 30,000.00 万元. 公司与汇丰银行（中国）有限公司珠海支行（以下简称"汇丰银行"）签署了《保 证书》，被担保人为丽珠单抗，担保期限为自单笔授信业务的主合同签订之日起 至债务人在该主合同项下的债务履行期限届满日后三年止，担保金额为人民币 50,000.00 万元。 ●截至 2023 年 11 月 30 日，公司对控股附属公司的担保总余额为 269,642.98 万元，占公司最近一期经审 ...

FF304 翌日披露報表 (股份發行人 ── 已發行股本變動及/或股份購回) 表格類別： 股票 狀態： 新提交 (i) 上市發行人已收取其在是次發行應得的全部款項； 公司名稱： 麗珠醫藥集團股份有限公司 呈交日期： 2023年12月5日 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | | 於香港聯交所上市(註11) | 否 | | | 證券代號 (如於香港聯交所上市) | | 說明 | | | | | | | 發行股份 | (註6及7) | 股份數目 | 已發行股份佔 有關股份發行前的 現有已發行股份數目 百分比 (註4、6及7) | | 每股發行價 (註1及7) | 上一個營業日 的每股收市價 (註5) | 發行價較市值的折讓/ 溢價幅度(百分比) (註7) | | 於下列日期開始時的結存(註2) | 2023年11月30日 | 625,721,470 | | | | | | | 1). 其他 (請註明) | | -11,614,548 | 1.2414 ...

3、2022 年 12 月 6 日，公司通过集中竞价交易方式首次回购公司 A 股股份, 截至 2023 年 10 月 25 日，公司通过集中竞价交易方式回购了公司 A 股股份共计 11,614,548 股，占公司总股本的比例为 1.24%，购买的最高价为人民币 37.34 元/ 股，最低价为人民币 32.25 元/股，已使用的资金总额为人民币 402,016,931.96 元 （不含交易费用）。公司本次股份回购使用的资金总额及实际执行情况符合公司 董事会、股东大会审议通过的回购方案。 证券代码：000513、01513 证券简称：丽珠集团、丽珠医药 公告编号：2023-108 丽珠医药集团股份有限公司回购结果暨股份变动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 1、丽珠医药集团股份有限公司（以下简称"公司"）于 2022 年 10 月 25 日 召开了公司 2022 年第三次临时股东大会、2022 年第三次 A 股类别股东会及 2022 年第三次 H 股类别股东会，审议通过了《关于回购公司部分 A 股股份方案的议 案》,公司使用自有资 ...

2023 年 12 月 1 日，丽珠医药集团股份有限公司（以下简称"本公司"）控 股附属公司珠海市丽珠单抗生物技术有限公司（以下简称"丽珠单抗"）收到国 家相关部门的函件，丽珠单抗研发生产的重组新型冠状病毒融合蛋白二价（原型 株/Omicron XBB 变异株）疫苗（CHO 细胞）（以下简称"本品"）经国家卫生健 康委提出建议，国家药品监督管理局（以下简称"国家药监局"）组织论证同意 纳入紧急使用。本品是继重组新型冠状病毒融合蛋白疫苗（丽康 V-01）之后，本 公司第二款被国家纳入紧急使用的新冠疫苗产品。 一、产品的基本情况 本品是丽珠单抗在丽康 V-01 的基础上开发的改良型疫苗。2023 年 7 月，丽 珠单抗收到国家药监局核准签发的《药物临床试验批件》（批件号 2023L90009）， 应急批准本品进行临床试验。有关详情请见公司于 2023 年 7 月 15 日发布的《关 于重组新型冠状病毒融合蛋白二价（原型株/Omicron XBB 变异株）疫苗（CHO 细胞）获得药物临床试验批件的公告》（公告编号：2023-063）。 证券代码：000513、01513 证券简称：丽珠集团、丽珠医药 公告编号：20 ...

证券代码：000513、01513 证券简称：丽珠集团、丽珠医药 公告编号：2023-104 丽珠医药集团股份有限公司 中长期事业合伙人持股计划之第三期持股计划实施进展的公告 特此公告。 丽珠医药集团股份有限公司董事会 2023 年 11 月 23 日 本公司及董事会全体成员保证信息披露内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 丽珠医药集团股份有限公司（以下简称"公司"）于 2023 年 11 月 7 日召开 了公司 2023 年第二次临时股东大会，审议通过了《关于公司〈中长期事业合伙 人持股计划之第三期持股计划（草案）〉及其摘要的议案》等相关议案，同意公 司实施中长期事业合伙人持股计划之第三期持股计划并授权公司董事会办理相 关事宜。有关详情请见公司于 2023 年 11 月 8 日在巨潮资讯网（www.cninfo.com.cn） 上披露的相关公告。 根据《关于上市公司实施员工持股计划试点的指导意见》及《深圳证券交易 所上市公司自律监管指引第 1 号——主板上市公司规范运作》的要求，现将公司 中长期事业合伙人持股计划之第三期持股计划的实施进展情况公告如下： 2023 年 11 月 22 ...

Financial Performance - The company's operating revenue for Q3 2023 was approximately ¥2.96 billion, a decrease of 6.93% compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2023 was approximately ¥481.87 million, an increase of 4.18% year-on-year[4] - For the first nine months of 2023, the total operating revenue reached approximately ¥9.65 billion, reflecting a year-on-year growth of 1.76%[8] - The basic earnings per share for Q3 2023 was ¥0.50, down 3.85% from the previous year[4] - The net profit attributable to shareholders of the parent company was RMB 1,601,554,878.96, representing a year-on-year increase of 6.3% from RMB 1,506,800,118.40[17] - The total comprehensive income for the first nine months was RMB 1,574,273,032.51, compared to RMB 1,660,625,774.20 in the previous year, showing a decline of 5.2%[18] Assets and Liabilities - The company's total assets as of the end of Q3 2023 were approximately ¥24.80 billion, a slight decrease of 0.26% from the end of the previous year[5] - As of the end of Q3 2023, current assets totaled RMB 16,984,391,531.73, slightly down from RMB 16,987,297,040.38 at the beginning of the year[15] - Total liabilities increased to RMB 10,331,726,594.21 from RMB 9,928,573,774.51, marking an increase of about 4.05%[16] - Long-term borrowings rose significantly to RMB 2,428,728,610.19 from RMB 1,974,444,042.88, representing an increase of approximately 22.94%[16] - The company's total equity decreased to RMB 14,468,236,857.29 from RMB 14,936,251,591.72, a decline of about 3.14%[16] - The total liabilities to equity ratio increased, indicating a higher leverage position for the company compared to the previous period[16] Cash Flow and Investments - Investment cash inflow increased significantly to ¥457,840,165.72, up 543.62% from ¥71,135,583.20 in the same period last year, primarily due to the recovery of investment funds[9] - Net cash flow from financing activities decreased to -¥1,768,301,850.08, a decline of 133.41% compared to -¥757,588,971.12 in the previous year, mainly due to reduced new borrowings and payments for share repurchases[9] - The cash flow from operating activities generated a net amount of RMB 2,212,403,355.39, up from RMB 1,847,923,769.75 in the same period last year, indicating a growth of 19.7%[19] - The company's investment activities resulted in a net cash outflow of RMB -553,929,894.90, an improvement from RMB -769,052,038.33 in the same period last year[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 45,778, with the top ten shareholders holding significant stakes, including Hong Kong Central Clearing Limited at 33.09%[11] - The company repurchased a total of 11,614,548 A shares, accounting for 1.24% of the total share capital, with a total expenditure of ¥402,016,931.96[13] - The highest repurchase price was ¥37.34 per share, while the lowest was ¥32.25 per share[13] - The company’s major shareholder, Health元 Pharmaceutical Group, holds 23.66% of the shares, indicating a strong influence on corporate governance[11] Operational Insights - The company reported a significant decrease of 72.23% in contract liabilities, amounting to approximately ¥62.81 million, due to revenue recognition of previously received payments[8] - The company experienced a 55.66% decrease in construction in progress, totaling approximately ¥267.12 million, attributed to the completion of new production lines[8] - The revenue from traditional Chinese medicine products increased by 50.17% year-on-year, reaching approximately ¥1.25 billion in the first nine months of 2023[8] - The company reported a decrease in sales expenses to RMB 2,814,431,433.12, down from RMB 2,902,292,445.97, reflecting a reduction of 3.0%[17] Financial Ratios and Expenses - The weighted average return on equity for the first nine months of 2023 was 11.38%, an increase of 0.04 percentage points year-on-year[4] - Research and development expenses amounted to RMB 985,755,413.94, which is a marginal increase from RMB 978,746,743.57 in the previous year[17] - The financial expenses showed an improvement, with a net financial cost of RMB -216,475,683.51 compared to RMB -254,166,791.47 in the previous year[17] Miscellaneous - The third quarter report of Livzon Pharmaceutical Group Co., Ltd. is unaudited[20] - The report was released on October 25, 2023[20] - No specific financial performance metrics or user data were provided in the report[20] - Future outlook and performance guidance were not detailed in the report[20] - There was no mention of new product or technology development in the report[20] - Market expansion and acquisition strategies were not discussed in the report[20] - Other new strategies were not highlighted in the report[20] - The report does not include any specific revenue or profit figures[20] - No comparative performance data or percentage changes were provided[20] - The report lacks detailed insights into operational performance[20]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產 生或因倚賴該等內容而引致的任何損失承擔任何責任。 麗 珠醫 藥集 團股 份有 限公 司 LIVZON PHARMACEUTICAL GROUP INC.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：1513） 2023年第三季度報告 麗珠醫藥集團股份有限公司Livzon Pharmaceutical Group Inc.*（「公司」或「本公司」，連同其 附屬公司，統稱「本集團」）根據香港聯合交易所有限公司證券上市規則第13.09條和第13.10B 條以及香港法例第571章證券及期貨條例第XIVA部內幕消息條文刊發本公告。 本公司及董事會全體成員保證信息披露的內容真實、準確、完整，沒有虛假記載、誤導性陳 述或重大遺漏。 重要內容提示： 1. 本公司董事會、監事會及董事、監事、高級管理人員保證公司2023年第三季度報告（「本 季度報告」）的真實、準確、完整，不存在虛假記載、誤導性陳述或重大遺漏，並承擔 ...